<SEC-DOCUMENT>0001213900-26-019042.txt : 20260223
<SEC-HEADER>0001213900-26-019042.hdr.sgml : 20260223
<ACCEPTANCE-DATETIME>20260223090028
ACCESSION NUMBER:		0001213900-26-019042
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260223
FILED AS OF DATE:		20260223
DATE AS OF CHANGE:		20260223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		26662255

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0277961-6k_ascentage.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of <B>February 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53.3pt 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2026, Ascentage
Pharma Group International issued a press releases entitled &ldquo;Ascentage Pharma to Participate in Three Upcoming Investor Conferences&rdquo;.
A copy of the press release is furnished as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Title</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 9%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea027796101ex99-1_ascentage.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated February 23, 2026</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 23, 2026</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027796101ex99-1_ascentage.htm
<DESCRIPTION>PRESS RELEASE DATED FEBRUARY 23, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ascentage Pharma to Participate in Three Upcoming
Investor Conferences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROCKVILLE, Md. and SUZHOU, China, February 23,
2026 -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;<B>As<FONT STYLE="font-family: Times New Roman, Times, Serif">centage
Pharma</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo; or the &ldquo;<B>Company,</B><FONT STYLE="font-size: 10pt; color: #1C1C1C; background-color: #F8F8F9">&nbsp;</FONT>a
global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel,
differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate
in three upcoming investor conferences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oppenheimer
                                            36th Annual Healthcare Life Sciences Conference: Presentation at 9:20 am EST on February
                                            25<SUP>th</SUP></FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                                                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">TD
                                            Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 am EST on March 4<SUP>th</SUP></FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jefferies
                                            Biotech on the Beach Summit: One-on-one meetings on March 10<SUP>th</SUP> &amp; 11<SUP>th</SUP></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
webcasts for the presentation and fireside chat will be accessed by visiting the Events page in the Investor Relations section of Ascentage&rsquo;s
we</FONT>bsite.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Ascentage Pharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (&ldquo;Ascentage Pharma&rdquo; or the &ldquo;Company&rdquo;) is a global,
commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated
therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that
includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lead asset, Olverembatinib, is the first novel
third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations,
CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs.
All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared,
global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for
patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s second approved product, Lisaftoclax,
is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following
National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting
four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients
with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with
newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4
study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S.
FDA, the EMA of the EU, and China CDE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leveraging its robust R&amp;D capabilities, Ascentage
Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with
numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to
research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National
Cancer Institute and the University of Michigan. For more information, visit&nbsp;https://ascentage.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained
in this press release may be forward-looking statements, including statements that express Ascentage Pharma&rsquo;s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are subject to
a number of risks and uncertainties as discussed in Ascentage Pharma&rsquo;s filings with the SEC, including those set forth in the sections
titled &ldquo;Risk factors&rdquo; and &ldquo;Special note regarding forward-looking statements and industry data&rdquo; in its Registration
Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the
sections headed &ldquo;Forward-looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; in the prospectus of the Company for its Hong
Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we
made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation
do not constitute profit forecast by the Company&rsquo;s management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of these factors, you should not rely
on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are
based on Ascentage Pharma&rsquo;s current expectations and beliefs concerning future developments and their potential effects and speak
only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts<BR>
Investor Relations:<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yuly Chen, Senior Investor Relations Director<BR>
Ascentage Pharma<BR>
IR@ascentage.com<BR>
+86 512 85557777</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (301) 792-5658</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephanie Carrington<BR>
ICR Healthcare<BR>
AscentageIR@icrhealthcare.com<BR>
+1 (646) 277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations:</B><BR>
Sean Leous<BR>
ICR Healthcare<BR>
AscentagePR@icrhealthcare.com<BR>
+1 (646) 866-4012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "< 9X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\Y]JY\%A/;OFELCJQN,]A[L=V>IO\8K7=\FESX]W%-_X7%!_T"Y?^^Q7&0>
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M2=9L];TY;VQE$D3?FI]#[U\]>(=&;0=:GT]IEF\O!#KW!_K77_"2_ECURYL
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M(&!(_"J\^B:9<G,]C;R'WC%%#&JE#DE'05? ^VGSPD?-4<=Q>W 2-9)YG.
M"S&O9_AQX0GT*VDO[Y=MU<  1_W%]_>NSMM+L;,?Z-:0Q8Z;4 JW4XG'NK'D
MBK(O#9>J4N>3NSDO&O@V'Q/9B2(K'?Q ^7(>C#^Z?:O$-3T?4-'N##?VLD+
MX!(^4_0]#7TY4,UM#<+MFB20>C*#2PV.G17*]45B<!"L^9:,^6ZZKPIX(O\
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M( &2>PKV+X40:C;Z?>PW=K+%;,P:,R#&3WX-=S!HNF6QS!8V\9_V8Q5X  8
MK?$X_P!M'D43GPV7NC/G<CP/QOX2N]"U6>X2)Y+&9RZ2 <+DYP?2L&PUW5-+
MB>.QOYX$<Y98VP#7TO)$DJ%)$#J>H89%45T#25F\U=.MA)G.[RQ5PS%<G)4C
M<BIEKY^:G*QX+9^&=;UFTNM3\B1HXT,ADDSF3_=SUK8^%L<A\9*VQMJP/N..
ME>XK&JH$55"XQ@#BF1VT,))CB1">I50*B>82G!P:T9<,M4)J:>Q\_>.[F6Y\
M9ZCYK%O+D\M?91T%=1\//"_A_6=(EFOBL]V7*F(O@QKV./ZU;^(_@J6>XEUR
MQ*8VYGC8A>G\0)KRM)9(B3&[(>^TXKT:7[_#J-.5FCS*MZ&(<JD;GN7_  K'
MPM_SQE_[_M70:1H.DZ*FW3[6*(D8+ 98_4U\X"\N?^?B;_OLU+!J=];2K+#>
M3HZ]&$AXK"6!JR5G4N=$<?2@[JG8^H*X7Q]X(_X2"+[?8X74(UP5/25?3ZUF
M_#_Q]/J5RFDZJX>=A^YF[O['WKTRO,:J86KYGJIT\72\CY=O+"[TZX,%Y;R0
M2J?NNN/_ -=0%F; ))].:^H+BQM;L8N+>.4?[:@U7AT+2K9MT.GVZ'U$8KT5
MFBMK'4\YY4[Z2T/'_ /A?7)=;MM2B22SMHG!>1P1O7NH'?->X4*H48 P!2UY
MF(KNO/F:/4PV'5"'*F+1117.=(4444 %%%% $<H8PN%^\5./K7S%J4%W:ZG<
M17X<7:R'S"_4G/6OJ"N6\6^"K+Q- 9,"&^482<#K['U%=^!Q,:,WS+1GG8_#
M2K13B]4<%X5\:FYTQM U6\D@#+MM[P-RGHK'T]ZZ>V\4ZEX>F6TUR(SVY_U=
MW'SN'8^]>3:SH&HZ!=&"_MVC.?ED'*O]#6KH?C.YTVW%A?PK?Z=T\F7JO^Z>
MU>G4PL)KGIJZ?3_(\>.(J1:4FTU_6I[G8:SI^IQA[2ZCDSSM!^8?AUJ_FO'8
M-/T76\2Z#JHMKAO^72Y;:0?0'_\ 75IIO&FD$@FZD7. 0/-']:\Z6#BW:,K>
M3T.Z.95(+]Y"_FCUFC..]>.OXX\11,4DN0C#J&A4$?I5.X\5ZY=D!K^89[1_
M+G\J<<NJ/=H4LYI):1?W'KVH:UI^EQEKNZCCX^[GYC^'6O/?$/C^>]5K;3 T
M$)&&E/WC]/2N<AT36+^3Y+&Z<GG<ZD _B:U5\*0:<@G\0:I;V4>,^4K;I"/\
M^@-==/#8>B[S?,^QY];'8S$KEIQY496A?;)-=M3:F1IO,!)4\XSSG\*]AEUZ
MP@U>WTHS;KR8$B-!G:/5O2O.;+6)]0<Z7X*TTPH3MEOYAR!ZY[?SKN?#/A6W
MT")I7D:YOYN9KF3EF/H/05S8V<9OF:MV7^9WY91G2BXIWONSHJ***\L]T***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@]* /'?
MBQK=P^IQZ1&[)!&@D< \.QZ5B_#K1=.UK7WCU':ZQ1[TA;HY_P#K5U7Q3\+W
M%T\>LV<1DV)MG51DX'1J\LM;J>RN4N+:9X9D.5=#@BOH\,E4PO)3=F?,8ING
MB>:HKH^E(]$TN*/RX["W5,=!&*\E^*&B:5I5[:2V$:02S ^9"G P.C8K*'Q(
M\4"+RQJ"XQC)B7/YXKG+Z_NM1N6N;RXDGF;J[G)K/"X2M3J<TY:&F*QE&K3Y
M81U+.@,Z^(M-,18-]ICQMZ_>&?TKZ8'05XY\-/"-S<:A'K=W&8[>'F ,.9&]
M?I7L@KCS*I&=1*/0[LLI2A3;EU%HHHKS#U0HHHH **** "BBB@ HHHH ****
M *E]I]IJ5LUO>6\<\3=5=<UYSKGPC@E+2Z-=>2QY$$V67Z!NH_6O4**VI8BI
M2?N,YZN'IU5[Z/G74/!/B+2G)DTV:10<![<>8#[\<_F*BL_$_B#1V$45_<Q!
M./*ER0/^ M7T?C-0R6L$HQ)"C ^J@UWK,>96J13//>6<KO3E8\,MOB9KL/\
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M86BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
